Free Content Duodenal ulcer healing with 1-week eradication triple therapy followed, or not, by anti-secretory treatment: a multicentre double-blind placebo-controlled trial

Author: Colin, R.1

Source: Alimentary Pharmacology & Therapeutics, Volume 16, Number 6, June 2002 , pp. 1157-1162(6)

Publisher: Blackwell Publishing

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content

Abstract:

Background:

In the management of Helicobacter pylori induced duodenal ulcer, it is still controversial whether anti-secretory treatment needs to be continued following a 1-week course of eradication therapy. Methods:

150 patients with H. pylori active duodenal ulcer (diameter ≥ 5 mm) were included. After a 1-week eradication treatment combining omeprazole 20 mg b.d., amoxicillin 1000 mg b.d. and clarithromycin 500 mg b.d. (OAC), patients were randomized to omeprazole 20 mg or placebo for 3 additional weeks. The primary variable was ulcer healing assessed at 4 weeks. Eradication was verified 4 weeks after cessation of study drugs by 13C-urea breath test. Intention-to-treat analysis (ITT) included 131 patients with positive histopathology at inclusion. Results:

Healing rates were not statistically different, at 89% and 87%, respectively, in the OAC-omeprazole and OAC-placebo groups (95% CI: -8.7; 13.7). Numerically, healing rates in patients with successful eradication was higher [94/104 (90%)] than in patients with failed eradication [21/27 (78%)]. However, the difference was not statistically significant (P < 0.1). Conclusions:

One-week OAC eradication triple therapy achieves excellent healing rates in patients with uncomplicated duodenal ulcer disease. Although the confidence interval of the difference in healing suggests little or no benefit of continued omeprazole treatment after 1 week, larger studies are needed to address this issue definitively.

Document Type: Research article

DOI: 10.1046/j.1365-2036.2002.01260.x

Affiliations: 1: CHU Charles Nicolle, Rouen, France

You have access to the full text article on a website external to Ingentaconnect.

Please click here to view this article on InterScience.

You may be required to register and activate access on InterScience before you can obtain the full text. If you have any queries please contact onlinehelp@oxon.blackwellpublishing.com

Back to top

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages.
Page Help Click here for Page Help
Shopping cart
Tools
Sign in






Need to register?
Sign up here
Text size: A | A | A | A